These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27785654)

  • 1. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    Campbell MJ; Baehner F; O'Meara T; Ojukwu E; Han B; Mukhtar R; Tandon V; Endicott M; Zhu Z; Wong J; Krings G; Au A; Gray JW; Esserman L
    Breast Cancer Res Treat; 2017 Jan; 161(1):17-28. PubMed ID: 27785654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
    Chen XY; Yeong J; Thike AA; Bay BH; Tan PH
    Breast Cancer Res Treat; 2019 Aug; 177(1):17-27. PubMed ID: 31134489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent.
    Agahozo MC; Westenend PJ; van Bockstal MR; Hansum T; Giang J; Matlung SE; van Deurzen CHM
    Mod Pathol; 2020 Sep; 33(9):1773-1782. PubMed ID: 32341499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
    Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
    Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immune microenvironment of breast ductal carcinoma in situ.
    Thompson E; Taube JM; Elwood H; Sharma R; Meeker A; Warzecha HN; Argani P; Cimino-Mathews A; Emens LA
    Mod Pathol; 2016 Mar; 29(3):249-58. PubMed ID: 26769139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.
    Chen XY; Thike AA; Koh VCY; Nasir NDM; Bay BH; Tan PH
    Virchows Arch; 2021 Apr; 478(4):679-686. PubMed ID: 33140128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
    Miligy I; Mohan P; Gaber A; Aleskandarany MA; Nolan CC; Diez-Rodriguez M; Mukherjee A; Chapman C; Ellis IO; Green AR; Rakha EA
    Histopathology; 2017 Aug; 71(2):258-268. PubMed ID: 28326600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).
    Darvishian F; Ozerdem U; Adams S; Chun J; Pirraglia E; Kaplowitz E; Guth A; Axelrod D; Shapiro R; Price A; Troxel A; Schnabel F; Roses D
    Ann Surg Oncol; 2019 Oct; 26(10):3337-3343. PubMed ID: 31240590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher densities of tumour-infiltrating lymphocytes and CD4
    Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
    Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional CD3
    Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.
    Lal A; Chan L; Devries S; Chin K; Scott GK; Benz CC; Chen YY; Waldman FM; Hwang ES
    Breast Cancer Res Treat; 2013 Jun; 139(2):381-90. PubMed ID: 23712790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.
    Toss MS; Miligy I; Al-Kawaz A; Alsleem M; Khout H; Rida PC; Aneja R; Green AR; Ellis IO; Rakha EA
    Mod Pathol; 2018 Aug; 31(8):1226-1236. PubMed ID: 29559742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
    Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
    BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.
    Ogiya R; Niikura N; Kumaki N; Bianchini G; Kitano S; Iwamoto T; Hayashi N; Yokoyama K; Oshitanai R; Terao M; Morioka T; Tsuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Cancer Sci; 2016 Dec; 107(12):1730-1735. PubMed ID: 27727484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer.
    Niwińska A; Olszewski WP
    Breast Cancer Res; 2021 Dec; 23(1):118. PubMed ID: 34952631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes.
    Kim A; Heo SH; Kim YA; Gong G; Jin Lee H
    Am J Clin Pathol; 2016 Jul; 146(1):137-44. PubMed ID: 27402610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
    Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
    Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ.
    Darvishian F; Wu Y; Ozerdem U; Chun J; Adams S; Guth A; Axelrod D; Shapiro R; Troxel AB; Schnabel F; Roses D
    Breast; 2022 Aug; 64():35-40. PubMed ID: 35489232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
    Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.